Analysts’ opinions on shares in the news Monday

From Standard & Poor’s Equity Research

Watch original video:

S&P MAINTAINS HOLD RECOMMENDATION ON SHARES OF CITIGROUP (C; 9.25):

In an unconfirmed report, Dow Jones reports that the size of Citigroup’s proposed, near-term work at jobs cuts, through layoffs and attrition has been increased to about 50,000, from earlier figures of 10,000. Citi is hosting a town hall meeting for employees today, in New York. On our concerns about possible future securities writedowns, we are charge our target recompense of $15, which is based on a 0.83 state of things multiple on Citi’s Sept. 30 equity book regard per share of $18.11. This is a discount to Citi’s historical multiples, and to chiefly peers. -S. Plesser, E. Oja

S&P LIFTS OPINION ON SHARES OF LOWE’S COMPANIES TO BUY FROM HOLD, ON VALUATION (LOW; 19.13):

October-quarter EPS of $0.33, vs. $0.43, is $0.03 above our set a value on. Comp-store sales declined 5.9%, and we expect challenging macroeconomic conditions will escort to negative comps throughout fiscal year 2010 (January). We are lowering our fiscal year 2009 and fiscal year 2010 EPS estimates to $1.51 and $1.36, from $1.54 and $1.55, and reducing our DCF-based target price to $25 from $30. However, LOW continues to gain marketshare, and we expect expense leverage once the housing place of traffic stabilizes. Trading at subordinate to 14 times our fiscal year 2010 EPS estimate in what we expect to have being its cyclical earnings trough, we find the shares attractive. -M. Souers

S&P MAINTAINS HOLD RECOMMENDATION ON SHARES OF GOLDMAN SACHS (GS; 63.54):

It was announced over the weekend that top executives at Goldman Sachs have voluntarily decided to forgo their 2008 bonuses in the wake of the downturn in the financial markets. The executives will have capacity for their establish. \ salaries, and it appears bonuses will still have being paid for the rest of the firm’s workforce. In light of the increased inquisition on Wall Street compensation, we are encouraged by the move and believe it is likely other top financial firms will come suit. We contend our 12-month target price of $95, roughly 1.0 times our 12-month plain book value projection, in put inside with peers. -M. Albrecht

S&P KEEPS BUY OPINION ON SHARES OF COVIDIEN LTD. (COV; 37.40):

September-quarter operating EPS of $0.73, vs. $0.62, is ten cents over our estimate. Sales were in line, but operating costs, pure interest expense and income tax rate were lower than we projected. At current rates, we think forex self-reliance negatively impact fiscal year 2009 (September) sales by means of dint of. 4%-6%, except get the start of that there will be some offset to earnings from lower raw stuff costs and tight operating cost controls. We are lowering financial year 2009 sales projection from $11.0 billion to $10.1 billion, EPS estimate by $0.10 to $3.00, and cutting our mark price by means of $20 to $43 based on forward PEG of 1.4 spells, modestly above peers. -R. Gold

S&P REITERATES BUY OPINION ON SHARES OF GILEAD SCIENCES (GILD; 46.91):

Teva Pharmaceuticals (TEVA; 43.09) files for permission to manufacture and market a generic version of Truvada, attempting to invalidate pair of GILD’s patents upon the physic. GILD claims Truvada is protected by 10 patents, all of which would need to be invalidated before a generic could have existence marketed. We expect GILD to file a patent infringement lawsuit, what one. would block FDA approval until at least 2011, and note Truvada’s patents force of will not expire to the time when 2017. As a result, we do not expect TEVA’s actions to result in a marketed drug. We keep our 12-month target price at $56. -S. Silver

Original text: {news-link}